Circulating antibodies to cysteinyl catecholamines in amyotrophic lateral sclerosis and Parkinson's disease patients.
Identifieur interne : 000568 ( Ncbi/Merge ); précédent : 000567; suivant : 000569Circulating antibodies to cysteinyl catecholamines in amyotrophic lateral sclerosis and Parkinson's disease patients.
Auteurs : L. Salauze [France] ; C. Van Der Velden ; I. Lagroye ; B. Veyret ; M. GeffardSource :
- Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases [ 1466-0822 ] ; 2005.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Amyotrophic Lateral Sclerosis (blood), Amyotrophic Lateral Sclerosis (immunology), Antibodies (blood), Catecholamines (chemistry), Catecholamines (immunology), Cysteine (chemistry), Cysteine (immunology), Female, Humans, Male, Middle Aged, Parkinson Disease (blood), Parkinson Disease (immunology).
- MESH :
- chemical , blood : Antibodies.
- blood : Amyotrophic Lateral Sclerosis, Parkinson Disease.
- chemical , chemistry : Catecholamines, Cysteine.
- immunology : Amyotrophic Lateral Sclerosis, Catecholamines, Cysteine, Parkinson Disease.
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged.
Abstract
Amyotrophic lateral sclerosis (ALS) is a degenerative disease of unknown aetiology, affecting motor neurons. Many radical species, such as O(2)(-) NO, and ONOO(-), and lipoperoxidative products are involved, but not all processes have yet been identified. It is known that the oxidation of catecholamines leads to quinone formation. These orthoquinones react with the sulphhydril group of cysteine to produce neurotoxic cysteinyl catecholamine (Cyst-CA) neo-compounds. We synthesised Cyst-CA in order to mimic their endogenous formation. Using the ELISA method, circulating antibodies to Cyst-CA were found in sporadic ALS sera. First, the antibody titres were compared to those of controls and patients with other neurodegenerative diseases. Significant antibody levels were found for Cyst-CA. The G and A isotypes were found but not the M isotype. A second series of experiments showed that A and G titres were elevated, depending on the type of Cyst-CA and the onset of the disease. IgG to Cyst-3,4-dihydroxyphenylalanine (L-DOPA) were present in cases of bulbar and upper limb onsets. IgA to Cyst-homovanillic acid (HVA), Cyst-adrenaline (A), and Cyst-dopamine (DA) were found in lower limb onset. These results indirectly show that: 1) the oxidation of CA and the formation of Cyst-CA may be involved in ALS; 2) these radical processes have different targets depending on the onset of the disease.
DOI: 10.1080/14660820510044469
PubMed: 16319026
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000F12
- to stream PubMed, to step Curation: 000E72
- to stream PubMed, to step Checkpoint: 000E72
Links to Exploration step
pubmed:16319026Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Circulating antibodies to cysteinyl catecholamines in amyotrophic lateral sclerosis and Parkinson's disease patients.</title><author><name sortKey="Salauze, L" sort="Salauze, L" uniqKey="Salauze L" first="L" last="Salauze">L. Salauze</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire PIOM, ENSCPB-EPHE, Pessac, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire PIOM, ENSCPB-EPHE, Pessac</wicri:regionArea><wicri:noRegion>Pessac</wicri:noRegion><wicri:noRegion>Pessac</wicri:noRegion></affiliation></author><author><name sortKey="Van Der Velden, C" sort="Van Der Velden, C" uniqKey="Van Der Velden C" first="C" last="Van Der Velden">C. Van Der Velden</name></author><author><name sortKey="Lagroye, I" sort="Lagroye, I" uniqKey="Lagroye I" first="I" last="Lagroye">I. Lagroye</name></author><author><name sortKey="Veyret, B" sort="Veyret, B" uniqKey="Veyret B" first="B" last="Veyret">B. Veyret</name></author><author><name sortKey="Geffard, M" sort="Geffard, M" uniqKey="Geffard M" first="M" last="Geffard">M. Geffard</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16319026</idno><idno type="pmid">16319026</idno><idno type="doi">10.1080/14660820510044469</idno><idno type="wicri:Area/PubMed/Corpus">000F12</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F12</idno><idno type="wicri:Area/PubMed/Curation">000E72</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E72</idno><idno type="wicri:Area/PubMed/Checkpoint">000E72</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E72</idno><idno type="wicri:Area/Ncbi/Merge">000568</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Circulating antibodies to cysteinyl catecholamines in amyotrophic lateral sclerosis and Parkinson's disease patients.</title><author><name sortKey="Salauze, L" sort="Salauze, L" uniqKey="Salauze L" first="L" last="Salauze">L. Salauze</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire PIOM, ENSCPB-EPHE, Pessac, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire PIOM, ENSCPB-EPHE, Pessac</wicri:regionArea><wicri:noRegion>Pessac</wicri:noRegion><wicri:noRegion>Pessac</wicri:noRegion></affiliation></author><author><name sortKey="Van Der Velden, C" sort="Van Der Velden, C" uniqKey="Van Der Velden C" first="C" last="Van Der Velden">C. Van Der Velden</name></author><author><name sortKey="Lagroye, I" sort="Lagroye, I" uniqKey="Lagroye I" first="I" last="Lagroye">I. Lagroye</name></author><author><name sortKey="Veyret, B" sort="Veyret, B" uniqKey="Veyret B" first="B" last="Veyret">B. Veyret</name></author><author><name sortKey="Geffard, M" sort="Geffard, M" uniqKey="Geffard M" first="M" last="Geffard">M. Geffard</name></author></analytic><series><title level="j">Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases</title><idno type="ISSN">1466-0822</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Amyotrophic Lateral Sclerosis (blood)</term><term>Amyotrophic Lateral Sclerosis (immunology)</term><term>Antibodies (blood)</term><term>Catecholamines (chemistry)</term><term>Catecholamines (immunology)</term><term>Cysteine (chemistry)</term><term>Cysteine (immunology)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (blood)</term><term>Parkinson Disease (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Amyotrophic Lateral Sclerosis</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Catecholamines</term><term>Cysteine</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Amyotrophic Lateral Sclerosis</term><term>Catecholamines</term><term>Cysteine</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Amyotrophic lateral sclerosis (ALS) is a degenerative disease of unknown aetiology, affecting motor neurons. Many radical species, such as O(2)(-) NO, and ONOO(-), and lipoperoxidative products are involved, but not all processes have yet been identified. It is known that the oxidation of catecholamines leads to quinone formation. These orthoquinones react with the sulphhydril group of cysteine to produce neurotoxic cysteinyl catecholamine (Cyst-CA) neo-compounds. We synthesised Cyst-CA in order to mimic their endogenous formation. Using the ELISA method, circulating antibodies to Cyst-CA were found in sporadic ALS sera. First, the antibody titres were compared to those of controls and patients with other neurodegenerative diseases. Significant antibody levels were found for Cyst-CA. The G and A isotypes were found but not the M isotype. A second series of experiments showed that A and G titres were elevated, depending on the type of Cyst-CA and the onset of the disease. IgG to Cyst-3,4-dihydroxyphenylalanine (L-DOPA) were present in cases of bulbar and upper limb onsets. IgA to Cyst-homovanillic acid (HVA), Cyst-adrenaline (A), and Cyst-dopamine (DA) were found in lower limb onset. These results indirectly show that: 1) the oxidation of CA and the formation of Cyst-CA may be involved in ALS; 2) these radical processes have different targets depending on the onset of the disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16319026</PMID><DateCreated><Year>2005</Year><Month>12</Month><Day>01</Day></DateCreated><DateCompleted><Year>2006</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1466-0822</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>4</Issue><PubDate><Year>2005</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases</Title><ISOAbbreviation>Amyotroph. Lateral Scler. Other Motor Neuron Disord.</ISOAbbreviation></Journal><ArticleTitle>Circulating antibodies to cysteinyl catecholamines in amyotrophic lateral sclerosis and Parkinson's disease patients.</ArticleTitle><Pagination><MedlinePgn>226-33</MedlinePgn></Pagination><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a degenerative disease of unknown aetiology, affecting motor neurons. Many radical species, such as O(2)(-) NO, and ONOO(-), and lipoperoxidative products are involved, but not all processes have yet been identified. It is known that the oxidation of catecholamines leads to quinone formation. These orthoquinones react with the sulphhydril group of cysteine to produce neurotoxic cysteinyl catecholamine (Cyst-CA) neo-compounds. We synthesised Cyst-CA in order to mimic their endogenous formation. Using the ELISA method, circulating antibodies to Cyst-CA were found in sporadic ALS sera. First, the antibody titres were compared to those of controls and patients with other neurodegenerative diseases. Significant antibody levels were found for Cyst-CA. The G and A isotypes were found but not the M isotype. A second series of experiments showed that A and G titres were elevated, depending on the type of Cyst-CA and the onset of the disease. IgG to Cyst-3,4-dihydroxyphenylalanine (L-DOPA) were present in cases of bulbar and upper limb onsets. IgA to Cyst-homovanillic acid (HVA), Cyst-adrenaline (A), and Cyst-dopamine (DA) were found in lower limb onset. These results indirectly show that: 1) the oxidation of CA and the formation of Cyst-CA may be involved in ALS; 2) these radical processes have different targets depending on the onset of the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salauze</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratoire PIOM, ENSCPB-EPHE, Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Velden</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lagroye</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Veyret</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Geffard</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Other Motor Neuron Disord</MedlineTA><NlmUniqueID>100964775</NlmUniqueID><ISSNLinking>1466-0822</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002395">Catecholamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>K848JZ4886</RegistryNumber><NameOfSubstance UI="D003545">Cysteine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002395" MajorTopicYN="Y">Catecholamines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003545" MajorTopicYN="Y">Cysteine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16319026</ArticleId><ArticleId IdType="pii">M3405525RG082702</ArticleId><ArticleId IdType="doi">10.1080/14660820510044469</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country></list><tree><noCountry><name sortKey="Geffard, M" sort="Geffard, M" uniqKey="Geffard M" first="M" last="Geffard">M. Geffard</name><name sortKey="Lagroye, I" sort="Lagroye, I" uniqKey="Lagroye I" first="I" last="Lagroye">I. Lagroye</name><name sortKey="Van Der Velden, C" sort="Van Der Velden, C" uniqKey="Van Der Velden C" first="C" last="Van Der Velden">C. Van Der Velden</name><name sortKey="Veyret, B" sort="Veyret, B" uniqKey="Veyret B" first="B" last="Veyret">B. Veyret</name></noCountry><country name="France"><noRegion><name sortKey="Salauze, L" sort="Salauze, L" uniqKey="Salauze L" first="L" last="Salauze">L. Salauze</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000568 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000568 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:16319026
|texte= Circulating antibodies to cysteinyl catecholamines in amyotrophic lateral sclerosis and Parkinson's disease patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:16319026" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |